13.14

1.72% -0.23

After Hours: 13.24 0.10 +0.76%

Tonix Pharmaceuticals Holding Corp (TNXP)

Overview News Price History Financials Why TNXP Down? Discussions Forecast Stock Split

Tonix Pharmaceuticals Holding Corp stock is traded at $13.14, with a volume of 252.19K. It is down -1.72% in the last 24 hours and up +17.22% over the past month. Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Previous Close:

$13.37

Open:

$13.3

24h Volume:

252.19K

Relative Volume:

0.48

Market Cap:

$225.36M

Revenue:

$13.11M

Net Income/Loss:

$-124.02M

P/E Ratio:

-0.9214

EPS:

-14.261

Net Cash Flow:

$-107.25M

1W Performance:

-3.31%

1M Performance:

+17.22%

6M Performance:

-6.01%

1Y Performance:

-50.06%

1-Day Range:

$12.99

$13.33

1-Week Range:

$12.99

$14.50

52-Week Range:

$9.40

$31.55

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Name

Tonix Pharmaceuticals Holding Corp

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

212-980-9155

Address

200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY

Employee

142

Twitter

@TONIXPharma

Next Earnings Date

2026-08-10

Latest SEC Filings

TNXP's Discussions on Twitter

Compare TNXP vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNXP Tonix Pharmaceuticals Holding Corp	13.14	212.50M	13.11M	-124.02M	-107.25M	-14.26
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-18-22	Initiated	Noble Capital Markets	Outperform
Apr-18-19	Upgrade	ROTH Capital	Neutral → Buy
Aug-18-17	Upgrade	ROTH Capital	Neutral → Buy
Sep-07-16	Downgrade	ROTH Capital	Buy → Neutral
Feb-17-16	Reiterated	Oppenheimer	Outperform
Nov-04-15	Initiated	Cantor Fitzgerald	Buy
Jun-12-15	Initiated	Oppenheimer	Outperform
Feb-17-15	Reiterated	ROTH Capital	Buy
Sep-29-14	Reiterated	ROTH Capital	Buy

View All

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News

Sep 06, 2026

TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits

Sep 06, 2026

Price-Driven Insight from (TNXP) for Rule-Based Strategy - news.stocktradersdaily.com

Sep 06, 2026

Sep 05, 2026

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits

Sep 05, 2026

Sep 02, 2026

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26 - Yahoo Finance

Sep 02, 2026

Tonix CEO will speak at a healthcare conference Sept. 10 - Stock Titan

Sep 02, 2026

Aug 31, 2026

Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com South Africa

Aug 31, 2026

Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen - marketbeat.com

Aug 29, 2026

Aug 24, 2026

Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Canada

Aug 24, 2026

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) Director Purchases $12,600.00 in Stock - MarketBeat

Aug 24, 2026

Aug 22, 2026

Tonix (TNXP) Market: Adds 1.29% to Close at $12.55; the Near-Term Reference Band Stretches From $11.92 to $13.18 in the Latest ReadingPositive Gamma - siam.in

Aug 22, 2026

Aug 19, 2026

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript - AOL.com

Aug 19, 2026

Aug 18, 2026

Tonix (TNXP) Daily Snapshot: Finishes 0.16% Higher at $12.68 in Latest Trading; the $12.05 to $13.31 Range Remains in Focus under the Current SnapshotValue Area High - Vinanet

Aug 18, 2026

Why TNXP Stock Is Suddenly Back On Retail Radar - stocktwits.com

Aug 18, 2026

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline - MarketBeat

Aug 18, 2026

Aug 17, 2026

Tonix Pharmaceuticals (TNXP) Holds Ground at $12.66 as Traders Eye $13.29 ResistanceTrend Reversal Picks - vinanet.vn

Aug 17, 2026

Aug 14, 2026

Tonix Pharmaceuticals Holding Corp. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TNXP) 2026-08-14 - Seeking Alpha

Aug 14, 2026

Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants - Stock Titan

Aug 14, 2026

Aug 13, 2026

AQR Capital discloses 5.54% ownership in Tonix Pharmaceuticals (TNXP) via Schedule 13G - Stock Titan

Aug 13, 2026

TNXP Q2 2026 Earnings: Better-Than-Expected Loss per Share, Shares Dip 3%Guidance Accuracy Score - Vinanet

Aug 13, 2026

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st

Aug 13, 2026

Aug 12, 2026

Tonix Pharmaceuticals Holding Corp.Common Stock (NQ: TNXP - FinancialContent

Aug 12, 2026

Industry Analysts Just Made A Dazzling Upgrade To Their Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Revenue Forecasts - Moomoo

Aug 12, 2026